Ulcerative Colitis IND Trial Application Cleared by FDA for InDex’s Cobitolimod
IBD News, News, Ulcerative colitis
The U.S. FDA has cleared InDex Pharmaceuticals AB’s Investigational New Drug (IND) application to launch a Phase 2b clinical trial for cobitolimod (Kappaproct) in patients with moderate to severe ulcerative colitis (UC). ... Read more